0001232524-21-000045 | 10-Q | XBRL Viewer

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2021	Jul. 27, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-33500
Entity Registrant Name	Jazz Pharmaceuticals plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1032470
Entity Address, Address Line One	Fifth Floor, Waterloo Exchange,
Entity Address, Address Line Two	Waterloo Road
Entity Address, City or Town	Dublin 4
Entity Address, Country	IE
Entity Address, Postal Zip Code	D04 E5W7
Country Region	353
City Area Code	1
Local Phone Number	634-7800
Title of 12(b) Security	Ordinary shares, nominal value $0.0001 per share
Trading Symbol	JAZZ
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		61,148,558
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal period Focus	Q2
Entity Central Index Key	0001232524
Current Fiscal Year End Date	--12-31

Certain Balance Sheet Items - Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Certain Balance Sheet Items [Abstract]
Rebates and other sales deductions	$ 211,939	$ 127,534
Sales returns reserve	25,875	18,368
Clinical trial accruals	25,666	9,108
Current portion of lease liabilities	20,879	14,457
Accrued interest	17,398	5,722
Inventory-related accruals	17,157	9,809
Accrued construction-in-progress	3,916	1,119
Accrued collaboration expenses	3,701	444
Accrued growing fees	3,072	0
Accrued milestones	$ 2,000	$ 0

Label	Element	Value
Business Acquisition, Transactions Costs Incurred During Period	jazz_BusinessAcquisitionTransactionsCostsIncurredDuringPeriod	$ 77,100,000
Business Acquisition, Transactions Costs Incurred During Period	jazz_BusinessAcquisitionTransactionsCostsIncurredDuringPeriod	84,000,000.0
Operating And Finance Lease, Liability	jazz_OperatingAndFinanceLeaseLiability	183,450,000
Operating And Finance Lease, Liability	jazz_OperatingAndFinanceLeaseLiability	154,492,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	119,194,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	28,008,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	159,383,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	56,665,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	13,400,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	92,800,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	76,500,000
Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment	jazz_CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	153,000,000.0
Deferred Tax, Intercompany Profit, Current	jazz_DeferredTaxIntercompanyProfitCurrent	160,825,000
Deferred Tax, Intercompany Profit, Current	jazz_DeferredTaxIntercompanyProfitCurrent	114,234,000
Debt Covenant, Outstanding Amount Threshold	jazz_DebtCovenantOutstandingAmountThreshold	50,000,000
Provision For Losses On Accounts Receivable And Inventory	jazz_ProvisionForLossesOnAccountsReceivableAndInventory	8,742,000
Provision For Losses On Accounts Receivable And Inventory	jazz_ProvisionForLossesOnAccountsReceivableAndInventory	4,078,000
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed During Period	jazz_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedDuringPeriod	29,000,000.0
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed During Period	jazz_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensedDuringPeriod	$ 346,900,000
FDA Recognition Of Orphan Drug Exclusivity, Period	jazz_FDARecognitionOfOrphanDrugExclusivityPeriod	7 years
Business Combination, Number Of American Depository Shares Acquired	jazz_BusinessCombinationNumberOfAmericanDepositorySharesAcquired	31,556,200
Payments to Acquire In Process Research and Development Other Than Through Business Combination	jazz_PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	$ 0
Payments to Acquire In Process Research and Development Other Than Through Business Combination	jazz_PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	205,250,000
Inventory, Step-Up Value	jazz_InventoryStepUpValue	992,500,000
U.K. Finance Act, Change In Tax Rate, Deferred Tax Liability, Income Tax Expense (Benefit)	jazz_UKFinanceActChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit	251,400,000
U.K. Finance Act, Change In Tax Rate, Deferred Tax Liability, Income Tax Expense (Benefit)	jazz_UKFinanceActChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit	251,400,000
Increase (Decrease) In Operating Lease Liabilities, Noncurrent	jazz_IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent	(8,790,000)
Increase (Decrease) In Operating Lease Liabilities, Noncurrent	jazz_IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent	(6,978,000)
Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities	jazz_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities	131,971,000
Inventory Step-Up Value Adjustment	jazz_InventoryStepUpValueAdjustment	65,991,000
Inventory Step-Up Value Adjustment	jazz_InventoryStepUpValueAdjustment	0
Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets (Liabilities)	jazz_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssetsLiabilities	35,194,000
Payment To Acquire Assets, Net Of Cash Acquired	jazz_PaymentToAcquireAssetsNetOfCashAcquired	6,234,792,000
Payment To Acquire Assets, Net Of Cash Acquired	jazz_PaymentToAcquireAssetsNetOfCashAcquired	0
Nonvoting Euro Deferred Shares	jazz_NonvotingEuroDeferredShares	55,000
Nonvoting Euro Deferred Shares	jazz_NonvotingEuroDeferredShares	55,000
Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature, Repurchase	jazz_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeatureRepurchase	(12,069,000)
Adjustments To Additional Paid In Capital, Convertible Debt With Conversion Feature, Repurchase	jazz_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeatureRepurchase	(12,069,000)
Finance Lease, Liability, To Be Paid, After Year Four	jazz_FinanceLeaseLiabilityToBePaidAfterYearFour	6,460,000
Lessee, Operating Lease, Liability, To Be Paid, After Year Four	jazz_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	99,899,000
Noncash Interest Expense	jazz_NoncashInterestExpense	38,010,000
Noncash Interest Expense	jazz_NoncashInterestExpense	29,268,000
Increase (Decrease) In Operating Lease Assets	jazz_IncreaseDecreaseInOperatingLeaseAssets	(7,893,000)
Increase (Decrease) In Operating Lease Assets	jazz_IncreaseDecreaseInOperatingLeaseAssets	(6,422,000)
Capital Redemption Reserve	jazz_CapitalRedemptionReserve	472,000
Capital Redemption Reserve	jazz_CapitalRedemptionReserve	472,000
Long-Term Debt, Maturity, After Year Four	jazz_LongTermDebtMaturityAfterYearFour	$ 6,203,250,000
Finite-Lived Intangible Asset, Measurement Input	jazz_FiniteLivedIntangibleAssetMeasurementInput	0.094
Proceeds From Issuance Of Term Loan	jazz_ProceedsFromIssuanceOfTermLoan	$ 3,719,930,000
Proceeds From Issuance Of Term Loan	jazz_ProceedsFromIssuanceOfTermLoan	$ 0
Licensing Agreement, Number Of Agreements	jazz_LicensingAgreementNumberOfAgreements	2
Income Tax Examination, Penalties And Interest Paid	jazz_IncomeTaxExaminationPenaltiesAndInterestPaid	$ 19,300,000
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs Not Expensed During Period	jazz_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostsNotExpensedDuringPeriod	280,100,000
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Costs Not Expensed During Period	jazz_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostsNotExpensedDuringPeriod	$ 299,900,000
FDA Stay Of Approval Period	jazz_FDAStayOfApprovalPeriod	30 months
Operating Lease And Finance Lease Right-Of Use Asset	jazz_OperatingLeaseAndFinanceLeaseRightOfUseAsset	$ 154,739,000
Operating Lease And Finance Lease Right-Of Use Asset	jazz_OperatingLeaseAndFinanceLeaseRightOfUseAsset	129,169,000
Contract With Customer, Liability, Increase (Decrease) For Governmental Grant	jazz_ContractWithCustomerLiabilityIncreaseDecreaseForGovernmentalGrant	484,000
Finite-Lived Intangible Asset, Expected Amortization, After Year Four	jazz_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	$ 4,563,761,000
Revenue, Performance Obligation, Payment Terms	jazz_RevenuePerformanceObligationPaymentTerms	30 days
Revenue, Performance Obligation, Payment Terms	jazz_RevenuePerformanceObligationPaymentTerms	45 days

Print Document View Excel Document
Cover Cover Notes Details Certain Balance Sheet Items - Accrued Liabilities (Details) Uncategorized Uncategorized Items - jazz-20210630_htm.xml All Reports